White Paper
Flow Cytometry-Based Receptor Occupancy Assays: Technical Challenges and Applications in Drug Development
UNLOCK THE POWER OF FLOW CYTOMETRY IN DRUG DEVELOPMENT
Discover how flow cytometry-based receptor occupancy assays (ROA) can drive innovation in clinical trial design, dose selection, and safety assessments. This white paper, authored by Jennifer J. Stewart, PhD, Vice President of Flow Cytometry Strategy at TD2, dives into the technical challenges and applications of ROA in drug development.
Download this White Paper to learn more about:
- The significance of ROAs in evaluating target receptor engagement.
- Integration of ROA data with pharmacokinetic (PK) and pharmacodynamic (PD) observations.
- Key requirements for effective ROA, including target expression and reagent detection.
- Addressing common challenges such as reagent availability, dim antigens, drug occupancy versus target expression, and specimen stability.
- Differences in ROA between preclinical and clinical settings and the importance of these assays in drug development pipelines.
- Real-world examples and detailed technical explanations, including the use of anti-drug antibodies (ADC) and non-competitive antibodies in ROA.
Download White Paper
About the Author
Jennifer J. Stewart, PhD
Vice President, Flow Cytometry Strategy at TD2
Dr. Jennifer Stewart has over 25 years of experience in oncology research with a focus on immunology. She has worked extensively in both academia and the CRO space, contributing to preclinical and clinical research for various drug development programs. At TD2, she leverages flow cytometry and predictive biomarkers to advance client programs. Dr. Stewart holds a PhD in Biochemistry and Molecular Biology, serves on the Board of the Northwest Flow Cytometry Society, and co-chairs the AAPS Flow Cytometry Action Programming Committee.
